Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States

Clinical Infectious Diseases

Volumn 32, Issue 3, 2001, Pages 476-482

  Mayer, K H ^a   Peipert, J ^a   Fleming, T ^a   Fullem, A ^a   Moench, T ^a   Cu Uvin, S ^a   Bentley, M ^a   Chesney, M ^a   Rosenberg, Z ^a  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BUFFER; REPROTECT;

ADULT; ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SPERM; UNITED STATES; UROGENITAL TRACT DISEASE; VAGINA;

ACRYLIC RESINS; ANTIVIRAL AGENTS; COLPOSCOPY; FEMALE; GELS; HIV INFECTIONS; HUMANS; HYDROGEN-ION CONCENTRATION; SAFETY; SEMEN; SPERMATOCIDAL AGENTS; UROGENITAL SYSTEM; VAGINA;

EID: 0035112881     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/318496     Document Type: Article

References (39)

1. Challenges for the development of female-controlled vaginal microbicides
2. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro
3. A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases
4. Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes
5. Safety of a nonoxynol-9 vaginal gel in Kenyan prostitutes: A randomized clinical trial
6. The effects of 3 nonoxynol-9 preparations on vaginal flora and epithelium
7. Safety study of nonoxynol-9 as a vaginal microbicide: Evidence of adverse effects
8. Quantitation of mediators of inflammation and immunity in general tract secretions and their relevance to HIV type 1 transmission
9. The rate human sperm are immobilized and killed by mild acidity
10. Inactivation of human immunodeficiency virus (HIV) by low pH and pepsin
11. Disinfection and inactivation of the human T lymphotropic virus type III/lymphadenopathy-associated virus
12. Acid sensitivity of cell-free and cell-associated HIV-1: Clinical implications
13. The activity of candidate virucidal agents, low pH, and genital secretions against HIV-1 in vitro
14. Comparative study of inactivation of simplex virus types 1 and 2 by commonly used antiseptic agents
15. Evaluating microbicides for prevention of Chlamydia infection using a mouse model of vaginal transmission
16. Tests of BufferGel in animal models for contraception and prevention of sexually transmitted diseases
17. Final report on the safety assessment of carbomers 934, 910, 934P, 940, 941, and 962
18. Role of urinary solutes in natural immunity to gonorrhea
19. Biology of Neisseria gonorrhoeae
20. Response of gonococcal clinical isolates to acidic conditions
21. Effect of pH on the motility and virulence of Treponema pallidum (Nichols) and Treponema paraluis cuniculi in vitro under anaerobic conditions
22. Characteristics of Haemophilus ducreyi in culture
23. Antibiosis between bacteria isolated from the vagina of women with and without signs of bacterial vaginosis
24. Acceptability of a novel microbicide during a phase I safety trial among low risk women
25. Recommendations for the development of vaginal microbicides
26. Phase 1 trial of the topical microbicide BufferGel: Safety results from four international sites
27. What is normal vaginal flora?
28. A dosing study on nonoxynol-9 and genital irritation
29. Safety study of nonoxynol-9 as a vaginal microbicide: Evidence of adverse effects
30. Frequent use of menfegol spermicidal vaginal foaming tablets associated with a high incidence of genital lesions
31. Effects of multiple applications of benzalkonium chloride and nonoxynol 9 on the vaginal epithelium in the pigtailed macaque (Macaca nemestrina)
32. Safety of a nonoxynol-9 vaginal gel in women at low risk of HIV infections
33. The effects of frequent nonoxynol use on the vaginal and cervical mucosa
34. Safety of a nonoxynol-9 vaginal gel in Kenyan prostitutes: A randomized clinical trial
35. Cervical-vaginal physiology and microbiology: Vaginal physiology during menstruation
36. Ethical challenges in efficacy trials of vaginal microbicides for HIV prevention